In summary, our findings suggest that MCL1 copy number or the MCL1:BCL-xL mRNA ratio may provide a rational enrichment strategy for identifying cancer patients whose tumors are most likely to respond to dinaciclib. This evidence concerns the gene BCL2L1 and cancer.